Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
Part of paid clinical trials in Abilene, Texas.
- Sponsor
- Bristol-Myers Squibb
- Study ID
- NCT01068704
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- BMS-690514 — DRUGTablets, Oral, 200 mg, once daily, \~ 12 months depending on response
- Lapatinib — DRUGTablets, Oral, 1500 mg, once daily, \~ 12 months depending on response
- Letrozole — DRUGTablets, Oral, 2.5 mg, once daily, \~ 12 months depending on response
Study Details
The purpose of this study is to determine if BMS-690514 + letrozole will be more effective than lapatinib + letrozole in patients who have metastatic hormone receptor positive breast cancer after developing progressive disease immediately following adjuvant antiendocrine therapy
Key Dates
- Start date
- Jun 30, 2010
- Status verified
- Sep 2015
- Primary completion
- Dec 31, 2010
- Completion
- Dec 31, 2010
Study Design
- Enrollment
- 4 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: BMS-690514 + Letrozole
- Active Comparator: Lapatinib + Letrozole
Primary Outcome Measure
Clinical Benefit Rate defined as percentage of subjects with a complete response, partial response, or stable disease for at least 6 months [ Time Frame: Every 8 weeks according to CT scan ]
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Texas Oncology-Abilene | Abilene | Texas | 79606 | - |
| Texas Oncology-Beaumont | Beaumont | Texas | 77702 | - |
| Us Oncology Central Pharmacy | Fort Worth | Texas | 76177 | - |
| Yakima Valley Memorial Hospital/North Star Lodge | Yakima | Washington | 98902 | - |
Find similar trials in Abilene, TX
By condition
By specialty
Related Studies
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPHASE2 · Recruiting · QuantumLeap Healthcare Collaborative · Birmingham, Alabama
- MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression ProfilesRecruiting · Agendia · Birmingham, Alabama
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast CancerPHASE3 · Recruiting · Canadian Cancer Trials Group · Fairbanks, Alaska